STAAR Surgical Company - Common Stock (STAA)
Frequently Asked Questions About STAAR Surgical Company - Common Stock (STAA)
Has STAAR Surgical been involved in any partnerships or collaborations?
Yes, STAAR Surgical has engaged in partnerships and collaborations with various clinical and research institutions, as well as healthcare professionals, to advance its technology development. These partnerships often provide valuable insights, facilitate clinical trials, and enhance the company's ability to innovate and reach new markets.
How does STAAR Surgical engage with its shareholders?
STAAR Surgical engages with its shareholders through regular communications, including quarterly earnings reports, annual shareholder meetings, and comprehensive financial disclosures. The company aims to maintain transparency and foster trust by providing updates on performance, strategic initiatives, and future outlooks.
How does STAAR Surgical support eye care professionals?
STAAR Surgical provides extensive support to eye care professionals through educational initiatives, training programs, and resources that enhance clinicians' understanding of its products and technologies. This includes clinical evidence, surgical techniques, and marketing support to help professionals successfully implement STAAR's solutions in their practices.
How has STAAR Surgical performed financially in recent years?
In recent years, STAAR Surgical has shown significant growth in revenue, driven by increasing adoption of its lens technologies and expanding market presence. The company's focus on R&D and introducing new products has contributed positively to its financial performance, though specific figures can fluctuate based on market conditions and operational challenges.
Is STAAR Surgical publicly traded?
Yes, STAAR Surgical is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol STAA. This means that its shares are available for purchase by the public, and the company's financial performance is subject to disclosure requirements set by regulatory authorities.
What are STAAR Surgical's research and development efforts focused on?
STAAR Surgical invests heavily in research and development to enhance its product offerings and develop new technologies. Their R&D efforts focus on improving lens design, expanding indications for various eye conditions, and exploring advanced surgical techniques to elevate patient outcomes and expand their market share.
What are the implications of the aging population for STAAR Surgical?
The aging population presents significant opportunities for STAAR Surgical, as age-related vision problems like cataracts and presbyopia increase. With a growing demographic needing effective vision correction solutions, STAAR's lens technologies may experience robust demand, supporting its growth strategy and expanding market share.
What are the key markets for STAAR Surgical?
STAAR Surgical primarily operates in the global ophthalmic medical device market, with a focus on countries experiencing strong demand for vision correction solutions. Key markets include the United States, Europe, and parts of Asia, where refractive surgeries and innovative lens technologies are in high demand.
What are the primary challenges facing STAAR Surgical?
STAAR Surgical faces several challenges, including intense competition from other medical device manufacturers, regulatory hurdles, and the constant need for innovation in the rapidly evolving ophthalmic market. Additionally, economic factors and changes in healthcare policies can impact healthcare spending and patient access to surgical treatments.
What does STAAR Surgical Company do?
STAAR Surgical Company specializes in the development, manufacturing, and marketing of implantable lenses for vision correction, specifically for patients with conditions such as cataracts and myopia (nearsightedness). Their primary products include the Visian ICL (Implantable Collamer Lens) and various other lens designs, offering patients alternatives to traditional corrective surgeries and eyewear.
What innovations has STAAR Surgical made in vision correction technology?
STAAR Surgical has made several innovations in vision correction technology, particularly with the Visian ICL, which utilizes Collamer, a polymer that combines both collagen and polymer, providing unique biocompatibility and UV protection. Their continuous enhancements in surgical techniques, lens designs, and adaptability to varying patient needs demonstrate their commitment to innovation.
What is the Visian ICL?
The Visian ICL, or Implantable Collamer Lens, is a product developed by STAAR Surgical that is designed to correct myopia and presbyopia. It is a biocompatible lens that is placed in the eye behind the iris, providing a minimally invasive alternative to LASIK and other refractive surgeries.
What is the vision and mission of STAAR Surgical?
STAAR Surgical's vision is to improve people's quality of life through innovative vision correction solutions. Its mission is focused on being the leading provider of innovative and effective ophthalmic medical devices, ensuring patient safety, and enhancing visual outcomes through advanced technology and compassionate patient care.
What regulatory approvals does STAAR Surgical need?
STAAR Surgical must obtain regulatory approvals from various health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), before marketing its products. These approvals ensure that their devices meet stringent safety and efficacy standards necessary for commercialization.
When was STAAR Surgical founded?
STAAR Surgical Company was founded in 1982. Since then, it has focused on innovating technology in the field of ophthalmology, particularly in refining lens technology and expanding the choices available to eye care professionals and patients.
Where can I learn more about STAAR Surgical?
You can learn more about STAAR Surgical by visiting their official website, which provides information on their products, corporate governance, recent news releases, and investor relations. Additionally, their social media platforms and industry publications can offer further insights into the company's activities and developments.
Where is STAAR Surgical headquartered?
STAAR Surgical Company is headquartered in Monrovia, California. This strategic location positions the company in proximity to key markets and provides access to a pool of talent and resources in the biotechnology and medical device industries.
Who are STAAR Surgical's competitors?
STAAR Surgical faces competition from several notable companies in the ophthalmic device sector, including Alcon, Johnson & Johnson Vision, and Bausch + Lomb. These competitors offer a range of vision correction products and technologies, which drives innovation and often leads to improved outcomes for patients.
What is the current price of STAAR Surgical Company - Common Stock?
The current price of STAAR Surgical Company - Common Stock is 17.06
When was STAAR Surgical Company - Common Stock last traded?
The last trade of STAAR Surgical Company - Common Stock was at 3:17 pm EDT on April 3rd, 2025
What is the market capitalization of STAAR Surgical Company - Common Stock?
The market capitalization of STAAR Surgical Company - Common Stock is 824.57M
How many shares of STAAR Surgical Company - Common Stock are outstanding?
STAAR Surgical Company - Common Stock has 48.33M shares outstanding.